Skip to main content
Search
Search
Advanced Search
Skip main navigation
Open access
Corrigendum
16 January 2024

Corrigendum

You are viewing the correction.
VIEW THE CORRECTED ARTICLE
Volume 13, Number 2
https://doi.org/10.57264/cer-2024-0003c1
PDF
The Review article by V Abitbol et al., ‘Navigating adalimumab biosimilars: an expert opinion’, which appeared in the November 2023 issue of the Journal of Comparative Effectiveness Research 12(11), e230117 (2023), was published with errors in Table 1.
Table 1. Characteristics of Humira® formulations and adalimumab biosimilars.
 Humira®Humira® (citrate free)Amgevita®/Amjevita®Imraldi®/Hadlima®Hyrimoz®Hulio®Idacio®Amsparity®Yuflyma®Hukyndra®
EU/US market†EU/USEU/USEU/US‡EU/USEU/USEUEUEUEU/USEU
Needle size (G) syringe27292929272929292929
Needle size (G) pen27292729272929292929
Pre-filled syringe/pen40 mg/-20 mg, 40 mg, 80 mg/ 40 mg, 80 mg20 mg,
40 mg/40 mg		40 mg/
40 mg		20 mg,
40 mg,
80 mg/
40 mg,
80 mg		20 mg, 40 mg/
40 mg		40 mg/
40 mg		20 mg,
40 mg/40 mg		40 mg,
80 mg/
40 mg,
80 mg		40 mg,
80 mg/
40 mg
CitrateYesNoNoNo§NoNoYesNoNoNo
LatexYesNoYesNoNoNoNoNoNoNo
Volume (ml) for 40 mg dose0.80.40.80.40.40.80.80.80.40.4
Availability of 80 mg formulationNoYes (since 16 Dec 2021)NoNoNoNoNoNoYesYes (syringe only)
Shelf life at 25°C, days141414312114
(20 mg in 0.4 ml sterile solution), 56
(40 mg in 0.8 ml sterile solution)		2830 (at 30°C)3114
†
As at 4 July 2023.
‡
High-concentration formulation expected to reach US market in 2024.
§
Imraldi®/Hadlima® has been citrate-free since the beginning of 2023.
The table included ‘Yes’ in the ‘Citrate’ row for Imraldi®/Hadlima®. However, the formulation has been citrate-free since the beginning of 2023.
In addition, in ‘Availability of 80 mg formulation’ row for Humira® (citrate free), the text was included as ‘Yes (pen only)’. However, it should have read ‘Yes (since 16 Dec 2021)’.
These points have now been corrected.
The authors and editors of the Journal of Comparative Effectiveness Research would like to sincerely apologize for any inconvenience or confusion this may have caused our readers.
|